Clancy Mullan, MD, PhD

Raised in Raleigh, North Carolina, Clancy attended the University of North Carolina at Chapel Hill for his undergraduate degrees in Chemistry (Biochemistry, Honors and Distinction) and Traditional Mathematics. While there, he worked in the Department of Genetics under Dr. Mark Heise, studying non-coding complementary strand transcription products of alphaviruses and working on validating a methodology of producing sequence independent cDNA libraries from multiple RNA viruses. He then attended the Donald and Barbara Zucker School of Medicine at Hofstra/Northwell. While a student, he studied the role of nicotinic signaling in mitochondrial membrane preservation during ischemic preconditioning with Dr. Kaie Ojamaa. He was selected for Alpha Omega Alpha and received the 2018 graduation award from the Department of Thoracic and Cardiovascular Surgery. Since joining the Yale Integrated Thoracic Surgery program, he has produced numerous outcomes research publications using institutional, national, and international databases. He completed his Doctor of Philosophy degree in 2024 under the mentorship of Dr. Jordan Pober, the Bayer Professor of Translational Medicine and Vice Chair of Immunobiology. He studied alloreactivity, microRNA-mediated regulation of endothelial cytokine expression, and novel nucleotide-based polymeric nanoparticle modification of endothelial cells and ex vivo perfused organs. He plans to pursue a career in surgical heart failure. He was awarded the 2024 Yale Department of Surgery Surgeon-Scientist Training Program to continue his translational science program, focused on the description and elimination of endothelial co-stimulatory molecules, while completing his clinical training. In 2025, he received the Frank C Detterbeck Resident Teaching Award from the Divisions of Cardiac and Thoracic Surgery. He plans to pursue a career in advanced heart failure.